The FDA Law Blog

FEBRUARY 28, 2023

Houck — The Drug Enforcement Administration’s (“DEA’s”) February 13th determination that THC acetate ester (“THCO”) is a schedule I controlled substance under the federal Controlled Substances Act (“CSA”) has received a good amount of attention in the cannabis press. By Larry K. Terrence L. Boos, Ph.D.,

Controlled Substances 58

Controlled Substances Compounding 58

Omnicell

SEPTEMBER 5, 2022

The operational blind spots caused by disconnected, siloed systems compounded by the delays and errors caused by outdated manual workflows are the hallmarks of operational complexity that impedes ideal perpetual inventory management and leads to financial strains that plague pharmacies.

Controlled Substances 98

Controlled Substances Omnicell Patient Care Hospitals 98

Omnicell

JANUARY 10, 2023

In the central pharmacy, our IVX Workflow management system , now supports decentralized compounding, enabling an sterile compounding workflow system now supports decentralized compounding, enabling an alternative way to compound new orders. healthcare system, compromising both patient and workforce safety.

Controlled Substances 52

Controlled Substances Omnicell Compounding Sterile Compounds 52

The FDA Law Blog

AUGUST 21, 2023

Attorney’s Office for the Western District of Texas announced that People’s Rx, a local chain operating five retail pharmacies and a compounding laboratory in the Austin area, agreed to pay $200,000 to settle allegations that it violated the Controlled Substances Act (“CSA”). 16, 2023 ( DOJ Press Release ).

Controlled Substances 52

Controlled Substances General Merchandise Stores Grocery Stores Compounding 52

The FDA Law Blog

JANUARY 18, 2024

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. HHS forwards FDA’s analysis and recommendation to DEA. 21 U.S.C. §

FDA 69

FDA Controlled Substances Chemotherapy Compounding 69

The FDA Law Blog

NOVEMBER 15, 2022

He also held leading roles in DOJ’s response to multiple significant national health crises, including the COVID-19 pandemic, the 2019 EVALI vaping crisis, and the 2012 New England Compounding Center fungal meningitis outbreak.

Compounding 52

Compounding Controlled Substances 52

Omnicell

SEPTEMBER 5, 2022

.” This CE-accredited session for pharmacy and nursing discussed how COVID-19 is compounding complications of Substance Use Disorder, and shared best practices for diversion monitoring in order to refocus resources and revise schedules amidst COVID-19.

Omnicell 52

Omnicell Controlled Substances Hospitals Documentation 52